Endometrial Cancer Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) - Estimates DelveInsight | GlaxoSmithKline, Eisai Co Ltd, MedImmune, On Target Laboratories, Sutro Biopharma, Netris Pharma

The Endometrial Cancer market is experiencing dynamic transformation, propelled by significant strides in oncology research and personalized medicine. As pharmaceutical and biotechnology firms intensify their efforts, there is a notable expansion in therapeutic options and diagnostic tools. This evolution is marked by heightened competition, a surge in clinical development activities, and a growing recognition of the importance of early detection and targeted treatments tailored to patients' unique molecular profiles.

DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Endometrial Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Endometrial Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Endometrial Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Endometrial Cancer: An Overview
Endometrial cancer develops when cells in the endometrium (the inner lining of the uterus) begin to grow out of control. Cancerous cells can arise in almost any portion of the body and spread to other parts. Endometrial cancer is sometimes called uterine cancer. Other types of cancer can form in the uterus, including uterine sarcoma, but they are much less common than endometrial cancer.

Endometrial cancer is often detected at an early stage because it frequently produces abnormal vaginal bleeding. If endometrial cancer is discovered early, removing the uterus surgically often cures endometrial cancer. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body.

The most common symptom of endometrial cancer is abnormal vaginal bleeding. This includes changes in the length or heaviness of menstrual periods, vaginal bleeding or spotting between menstrual periods, and vaginal bleeding after menopause. Other potential symptoms of endometrial cancer include watery or blood-tinged vaginal discharge, pain in the lower abdomen or pelvis, and pain during sex.

Surgery, radiation therapy, chemotherapy, hormone therapy, targeted drug therapy, immunotherapy, and supportive (palliative) care are some of the treatment options available for treating Endometrial Cancer. Total hysterectomy with bilateral salpingo-oophorectomy is the standard treatment for endometrial cancer. Treatment options include radiation and chemotherapy. Nonsurgical treatments are available for low- to medium-risk endometrial hyperplasia. The stage of the disease and histology are used to determine survival, with most patients in stages I and II having a good prognosis.

Get a Detailed Overview of the Evolving Endometrial Cancer Market Trends @
https://www.delveinsight.com/report-store/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Endometrial Cancer Market Key Facts
• According to the National Cancer Institute, approximately 3 in 100 women will be diagnosed with uterine cancer at some point in their lives. Endometrial cancer comprises about 4% of all cancers in women globally.
• According to the American Cancer Society, in the United States, the endometrium (the lining of the uterus) is the most common cancer of the female reproductive organs. As per American Cancer Society estimates for cancer of the uterus in the United States for 2022, about 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) will be diagnosed and about 12,550 women will die from cancers of the uterine body.
• As per Cancer Research UK, there are around 9,700 new uterine cancer cases in the UK every year, that is 27 every day (2016-2018).
• According to Palacios et al. (2022), in 2018, in Spain and France, the incidence rates were 13.7 and 14.7 cases/100,000 person-years.
• AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, and Incyte Corporation are some of the key players developing drugs for the treatment of Endometrial Cancer.

Endometrial Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Endometrial Cancer therapies in the market. It also provides a detailed assessment of the Endometrial Cancer market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Endometrial Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Endometrial Cancer Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Endometrial Cancer Epidemiology
The epidemiology section covers detailed insights into the historical, and current Endometrial Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Endometrial Cancer Epidemiology Segmented as -
• Total Endometrial Cancer Incident Cases
• Endometrial Cancer Stage-specific Incident Cases
• Endometrial Cancer Age-specific Cases
• Total Endometrial Cancer Treated Cases by line of therapies

Get Key Insights Into the Evolving Endometrial Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Endometrial Cancer Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometrial Cancer market or expected to be launched during the study period. The analysis covers the market share by Endometrial Cancer drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Endometrial Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Endometrial Cancer Market @
https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Endometrial Cancer Therapeutics Assessment
Surgery, radiation therapy, chemotherapy, hormone therapy, targeted drug therapy, immunotherapy, and supportive (palliative) care are some of the treatment options available for treating Endometrial Cancer. Total hysterectomy with bilateral salpingo-oophorectomy is the standard treatment for endometrial cancer. Treatment options include radiation and chemotherapy. Nonsurgical treatments are available for low- to medium-risk endometrial hyperplasia. The stage of the disease and histology are used to determine survival, with most patients in stages I and II having a good prognosis.

Several major pharma and biotech companies are developing therapies for Endometrial Cancer. Currently, GlaxoSmithKline is leading the therapeutics market with its Endometrial Cancer drug candidates in the mid to advanced stage of clinical development.

Leading Companies in the Endometrial Cancer Therapeutics Market Include
• GlaxoSmithKline
• Eisai Co Ltd
• MedImmune
• On Target Laboratories
• Sutro Biopharma
• Netris Pharma
And Many Others

Emerging and Marketed Endometrial Cancer Therapies Covered in the Report Include
• Dostarlimab: GlaxoSmithKline
• Lenvatinib (LENVIMA): Eisai Co Ltd
• KEYTRUDA (pembrolizumab): Merck & Co
• JEMPERLI (dostarlimab-gxly): GlaxoSmithKline Pharmaceuticals
• Lynparza (Olaparib) + Imfinzi DuO-E: AstraZeneca
• EG-007: Evergreen Therapeutics
And Many More

Learn More About the Emerging Therapies and key Companies in the Endometrial Cancer Therapeutics Market @
https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Endometrial Cancer Competitive Intelligence Analysis
4. Endometrial Cancer Market Overview at a Glance
5. Endometrial Cancer Background and Overview
6. Endometrial Cancer Patient Journey
7. Endometrial Cancer Epidemiology and Patient Population
8. Endometrial Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Endometrial Cancer Unmet Needs
10. Key Endpoints of Endometrial Cancer Treatment
11. Endometrial Cancer Marketed Products
12. Endometrial Cancer Emerging Therapies
13. Endometrial Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Endometrial Cancer Market Outlook (7 major markets)
16. Endometrial Cancer Access and Reimbursement Overview
17. KOL Views on the Endometrial Cancer Market.
18. Endometrial Cancer Market Drivers
19. Endometrial Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.